Chromogranin A in blood - A useful marker for neuroendocrine tumours;Kromogranin A i blod - En nyttig tumormarkør

Tidsskrift for den Norske Laegeforening

Volumn 117, Issue 26, 1997, Pages 3810-3811

  Syversen, Unni ^a   Heide, Liv S ^a   Waldum, Helge L ^a  

^a Medisinsk Avdeling   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN; TUMOR MARKER;

BLOOD; HUMAN; NEUROENDOCRINE TUMOR; REVIEW;

CHROMOGRANINS; HUMANS; NEUROENDOCRINE TUMORS; TUMOR MARKERS, BIOLOGICAL;

EID: 17144436929     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Huttner WB, Gerdes HH, Rosa P. The granin (chromogranin/secretogranin) family. Trends Biochem Sci 1991; 16: 27-30.
2. Helle KB. Some chemical and physical properties of the soluble protein fraction of bovine adrenal chromaffin granules. Mol Pharmacol 1966; 2: 298-310.
3. Parmer RJ, Xi X-P, Wu H-J, Helman LJ, Petz LN. Secretory protein traffic. Chromogranin A contains a dominant targeting signal for the regulated pathway. J Clin Invest 1993; 92: 1042-54.
4. Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ, Barchas JD. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 1986; 324: 476-8.
5. Galindo E, Zwiller J, Bader MF, Aunis D. Chromostatin inhibits catecholamine secretion in adrenal chromaffin cells by activating a protein phosphatase. Proc Natl Acad Sci USA 1992; 89: 7398-402.
6. Drees BM, Rouse J, Johnson J, Hamilton JW. Bovine parathyroid glands secrete a 26-kDa N-terminal fragment of chromogranin-A which inhibits parathyroid cell secretion. Endocrinology 1991; 129: 3381-7.
7. Helle KB, Aardal S, Reed RK, Elsayed S. N-terminal fragment of bovine chromogranin A inhibits the contractile response to endothelin-1 in human venous and arterial isolated segments. J Physiol 1990; 430: 40.
8. Schmid KW, Weiler R, Xu RW, Hogue-Angeletti R, Fischer-Colbrie R, Winkler H. An immunological study on chromogranin A and B in human endocrine and nervous tissues. Histochem J 1989; 21: 365-73.
9. Somogyi P, Hodgson AJ, De Potter RW, Fischer-Colbrie R, Schober M, Winkler H et al. Chromogranin immunoreactivity in the central nervous system. Immunochemical characterisation, distribution and relationship to catecholamine and enkephalin pathways. Brain Res 1984; 320: 193-230.
10. O'Connor DT. Radioimmunoassays of chromogranin. I: Krstulovic, red. Quantitative analysis of catecholamines and related compounds. London: John Wiley, 1986: 302-15.
11. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986; 314: 1145-51.
12. Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996; 39: 649-53.
13. Borch K, Stridsberg M, Burman P, Rehfeld JF. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 1997; 32: 198-202.
14. Syversen U, Waldum HL, O'Connor DT. Rapid, high-yield isolation of human chromogranin A from chromaffin granules of pheochromocytomas. Neuropeptides 1992; 22: 235-40.
15. Syversen U, Jacobsen MB, O'Connor DT, Rønning K, Waldum HL. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: Correspondence in patients with neuroendocrine neoplasia. Neuropeptides 1994; 26: 201-6.
16. Stridsberg M, Hellman U, Wilander E, Lundqvist G, Hellsing K, Øberg K. Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: development of a specific radioimmunoassay for chromogranin A and its fragments. J Endocrinol 1993; 139: 329-37.
17. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet 1963; i: 238-9.
18. Norheim I, Øberg K, Theodorsson-Norheim E, Lindgren PG, Lundqvist G, Magnusson et al. Malignant carcinoid tumors. Ann Surg 1987; 206: 115-25.
19. Stridsberg M, Øberg K, Li Q, Engstrøm U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995; 144: 49-59.
20. Syversen U, Jacobsen MB, Hanssen LE, O'Connor DT, Waldum HL. Chromogranin A and pancreastatin-like immunoreactivity in human carcinoid disease. Eur J Gastroenterol Hepatol 1993; 5: 1043-50.
21. Rindi G, Buffa R, Sessa F, Tortora O, Solcia E. Chromogranin A, B and C immunoreactivities of mammalian endocrine cells. Distribution, distinction from costored hormones/prohormones and relationship with the argyrophil component of secretory granules. Histochemistry 1986; 85: 19-28.
22. Syversen U, Mignon M, Bonfils S, Kristensen A, Waldum HL. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. Acta Oncol 1993; 32: 161-5.
23. Gazdar AF, Helman LJ, Israel MA, Russell EK, Linnola RI, Mulshine JL et al. Expression of neuroendocrine cell markers 1-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res 1988; 48: 4078-82.
24. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjølnerød OK, Waldum HL. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 1997; 30: 1-6.
25. Waldum HL, Haugen OA, Isaksen C, Mecsei R, Sandvik AK. Are diffuse carcinomas neuroendocrine tumors (ECL-omas)? Eur J Gastroenterol Hepatol 1991; 3: 245-9.
26. Sobol RE, O'Connor DT, Addison J, Suchocki K, Royston I, Deftos LJ. Elevated serum chromogranin A concentrations in small-cell lung carcinoma. Ann Intern Med 1986; 105: 698-700.
27. Johnson PWM, Joel SP, Love S, Butcher M, Pandian MR, Squires L et al. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer 1993; 67: 760-6.
28. Neumann HPH, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993; 329: 1531-8.
29. Hsiao RJ, Parmer RJ, Takiyyuddin MA, O'Connor DT. Chromogranin A storage and secretion: Sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine 1991; 70: 33-45.
30. Stridsberg M, Husebye ES. Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma. Eur J Endocrinol 1997; 136: 67-73.
31. Hsiao RJ, Seeger RC, Yu AL, O'Connor DT. Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival. J Clin Invest 1990; 85: 1555-9.
32. Hsiao RJ, Mezger MS, O'Connor DT. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 1990; 37: 955-64.